Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults
Authors not listed
Vanderbilt University · 2009
Abstract
Little is known about factors associated with maintenance of hemagglutinin inhibition (HAI) antibodies after influenza vaccination in older adults so the investigators enrolled adults ≥50 years.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-10 MST
Cite this
APA
Anonymous. (2009). Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults. <em>Vanderbilt University</em>. https://clinicaltrials.gov/study/NCT02401893
Vancouver
Anonymous. Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults. Vanderbilt University. 2009.
BibTeX
@misc{anon2009Factor,
title = {Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults},
author = {Anonymous},
journal = {Vanderbilt University},
year = {2009},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Abbott Biologicals 2009
Open access · US-GOV
Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Cell-Derived Trivalent Subunit Influenza Vaccine in Subjects Aged >= 18 Years and <= 64 Years During Two Consecutive Years.
New England Journal of Medicine 2024
Preprint · OA
Frailty in Older Adults
Innovation in aging 2025
Open access · OA
METFORMIN TO TARGET FRAILTY IN OLDER ADULTS
Seqirus 2023
Open access · US-GOV
A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc) in Comparison With Quadrivalent Influenza Vaccines, in Adults Aged 50 Years and Older.
GeroScience 2023
Preprint · OA
A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment
Yu Qin 2022
Open access · US-GOV